|
1
|
Trinh VA: Current management of metastatic
melanoma. Am J Health Syst Pharm. 65 Suppl 9:S3–S8. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mete M, Sirakov NM, Griffin J and Menter
A: A novel classification system for dysplastic nevus and malignant
melanomaProceedings of the IEEE International Conference on Image
Processing. Phoenix, AZ: pp. 3414–3418. 2016
|
|
3
|
Cho E, Rosner BA and Colditz GA: Risk
factors for melanoma by body site. Cancer Epidemiol Biomarkers
Prev. 14:1241–1244. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Trautmann F, Meier F, Seidler A and
Schmitt J: Effects of the German skin cancer screening programme on
melanoma incidence and indicators of disease severity. Br J
Dermatol. 175:912–919. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Whiteman DC, Green AC and Olsen CM: The
Growing Burden of Invasive Melanoma: Projections of Incidence Rates
and Numbers of New Cases in Six Susceptible Populations through
2031. J Invest Dermatol. 136:1161–1171. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ingrassia L, Lefranc F, Kiss R and
Mijatovic T: Naphthalimides and azonafides as promising anti-cancer
agents. Curr Med Chem. 16:1192–1213. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ralhan R and Kaur J: Alkylating agents and
cancer therapy. Expert Opin Ther Pat. 17:1061–1075. 2007.
View Article : Google Scholar
|
|
8
|
Xie L, Cui J, Qian X, Xu Y, Liu J and Xu
R: 5-Non-amino aromatic substituted naphthalimides as potential
antitumor agents: Synthesis via Suzuki reaction, antiproliferative
activity, and DNA-binding behavior. Bioorg Med Chem. 19:961–967.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhu H, Huang M, Yang F, Chen Y, Miao ZH,
Qian XH, Xu YF, Qin YX, Luo HB, Shen X, et al: R16, a novel
amonafide analogue, induces apoptosis and G2-M arrest via poisoning
topoisomerase II. Mol Cancer Ther. 6:484–495. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Antonini I, Volpini R, Dal Ben D,
Lambertucci C and Cristalli G: Design, synthesis, and biological
evaluation of new mitonafide derivatives as potential antitumor
drugs. Bioorg Med Chem. 16:8440–8446. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Braña MF, Cacho M, García MA, de
Pascual-Teresa B, Ramos A, Domínguez MT, Pozuelo JM, Abradelo C,
Rey-Stolle MF, Yuste M, et al: New analogues of amonafide and
elinafide, containing aromatic heterocycles: Synthesis, antitumor
activity, molecular modeling, and DNA binding properties. J Med
Chem. 47:1391–1399. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dumont P, Ribaucour F, Quaquebeke EV,
Darro F and Kiss R: UNBS3157, a new amonafide derivative with
improved in vivo efficacy and decreased toxicity. Cancer Res.
66:11052006.PubMed/NCBI
|
|
13
|
Van Quaquebeke E, Mahieu T, Dumont P,
Dewelle J, Ribaucour F, Simon G, Sauvage S, Gaussin JF, Tuti J, El
Yazidi M, et al:
2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl}carbamoyl)acetamide
(UNBS3157), a novel nonhematotoxic naphthalimide derivative with
potent antitumor activity. J Med Chem. 50:4122–4134. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Seliga R, Pilatova M, Sarissky M, Viglasky
V, Walko M and Mojzis J: Novel naphthalimide polyamine derivatives
as potential antitumor agents. Mol Biol Rep. 40:4129–4137. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mahieu T, Mijatovic T, Quaquebeke EV,
Lefranc F, Vynckt FV, Darro F and Kiss R: UNBS5162 is a novel
naphthalimide derivative that induces autophagy and senescence in
human prostate cancer cells. Mol Cancer Ther. 6:3373S2007.
|
|
16
|
Mijatovic T, Mahieu T, Bruyère C, De Nève
N, Dewelle J, Simon G, Dehoux MJM, van der Aar E, Haibe-Kains B,
Bontempi G, et al: UNBS5162, a novel naphthalimide that decreases
CXCL chemokine expression in experimental prostate cancers.
Neoplasia. 10:573–586. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Babchia N, Calipel A, Mouriaux F, Faussat
AM and Mascarelli F: The PI3K/Akt and mTOR/P70S6K signaling
pathways in human uveal melanoma cells: Interaction with B-Raf/ERK.
Invest Ophthalmol Vis Sci. 51:421–429. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang B, Shen J and Wang J: UNBS5162
inhibits proliferation of human retinoblastoma cells by promoting
cell apoptosis. OncoTargets Ther. 10:5303–5309. 2017. View Article : Google Scholar
|
|
19
|
Kiliçkan L, Gonca S, Dalçik C, Dalçik H,
Solak M, Bayindir O, Süzer K, Omay O and Calikan E: General
anesthesia with thoracic epidural anesthesia in the cardiopulmonary
bypass surgery reduces apoptosis by upregulating antiapoptotic
protein Bcl-2. J Cardiovasc Surg (Torino). 47:315–322.
2006.PubMed/NCBI
|
|
20
|
Siddiqui WA, Ahad A and Ahsan H: The
mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update.
Arch Toxicol. 89:289–317. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wojtuszkiewicz A, Schuurhuis GJ, Kessler
FL, Piersma SR, Knol JC, Pham TV, Jansen G, Musters RJ, van Meerloo
J, Assaraf YG, et al: Exosomes Secreted by Apoptosis-Resistant
Acute Myeloid Leukemia (AML) Blasts Harbor Regulatory Network
Proteins Potentially Involved in Antagonism of Apoptosis. Mol Cell
Proteomics. 15:1281–1298. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang L, Han J, Ben-Hail D, He L, Li B,
Chen Z, Wang Y, Yang Y, Liu L, Zhu Y, et al: A New Fungal Diterpene
Induces VDAC1-dependent Apoptosis in Bax/Bak-deficient Cells. J
Biol Chem. 290:23563–23578. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Singh L, Pushker N, Saini N, Sen S, Sharma
A, Bakhshi S, Chawla B and Kashyap S: Expression of pro-apoptotic
Bax and anti-apoptotic Bcl-2 proteins in human retinoblastoma. Clin
Experiment Ophthalmol. 43:259–267. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhu L, Han MB, Gao Y, Wang H, Dai L, Wen Y
and Na LX: Curcumin triggers apoptosis via upregulation of
Bax/Bcl-2 ratio and caspase activation in SW872 human adipocytes.
Mol Med Rep. 12:1151–1156. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou S, Wang Y and Zhu JJ: Simultaneous
Detection of Tumor Cell Apoptosis Regulators Bcl-2 and Bax through
a Dual-Signal-Marked Electrochemical Immunosensor. ACS Appl Mater
Interfaces. 8:7674–7682. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jiang H, Liu J, Gao J, Meng M, Qin X and
Wang T: Up-regulations of Bax and caspase-3 and down-regulation of
Bcl-2 after Xinfeng capsule treatment in adjuvant-induced arthritis
rats. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 32:457–461. 2016.(In
Chinese). PubMed/NCBI
|
|
27
|
Wang D, Chen J, Chen H, Duan Z, Xu Q, Wei
M, Wang L and Zhong M: Leptin regulates proliferation and apoptosis
of colorectal carcinoma through PI3K/Akt/mTOR signalling pathway. J
Biosci. 37:91–101. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kang S, Dong SM, Kim BR, Park MS, Trink B,
Byun HJ and Rho SB: Thioridazine induces apoptosis by targeting the
PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells.
Apoptosis. 17:989–997. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun CH, Chang YH and Pan CC: Activation of
the PI3K/Akt/mTOR pathway correlates with tumour progression and
reduced survival in patients with urothelial carcinoma of the
urinary bladder. Histopathology. 58:1054–1063. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiang Z, Liu Y and Wang C: Oncogenic
NanogP8 expression regulates cell proliferation and migration
through the Akt/mTOR signaling pathway in human gastric cancer -
SGC-7901cell line. OncoTargets Ther. 9:4859–4866. 2016. View Article : Google Scholar
|
|
31
|
Leleu X, Coiteux V, Corm S, Robu D, Dupire
S, Moreau AS, Gay J, Berthon C, Pascal L, Cliquenois E, et al: The
AKT signaling pathway is the key regulator of cell survival and
homing in Waldenstrom macroglobulinemia. Hématologie. 14:14–17.
2008.
|
|
32
|
Yang H, Zhou J, Mi J, Ma K, Fan Y, Ning J,
Wang C, Wei X, Zhao H and Li E: HOXD10 acts as a tumor-suppressive
factor via inhibition of the RHOC/AKT/MAPK pathway in human
cholangiocellular carcinoma. Oncol Rep. 34:1681–1691. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Asnaghi L, Bruno P, Priulla M and Nicolin
A: mTOR: A protein kinase switching between life and death.
Pharmacol Res. 50:545–549. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yu JS and Cui W: Proliferation, survival
and metabolism: The role of PI3K/AKT/mTOR signalling in
pluripotency and cell fate determination. Development.
143:3050–3060. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu YD, Zheng QX, Wu HB, Guo XD, Li JF and
Hao SF: The effects of rapamycin on expression ratio of Bax/Bcl-2
and the expression of activated caspase-3 in different types of
tumor cells. Tumor. 33(2)2013.
|
